Sanofi suffers multiple sclerosis setback


French pharmaceutical Sanofi has run into trouble after the US Food and Drug Administration (FDA) rejected its multiple sclerosis drug Lemtrada (alemtuzumab). The agency said that its rejection of alemtuzumab was the result of poor Phase III clinical trial design and side effects that outweigh the potential benefits.

When Sanofi bought Genzyme for more than $20 billion (£12 billion) in February 2011, additional milestone payments were agreed, depending on the success of alemtuzumab. The monoclonal antibody was approved to treat multiple sclerosis in the EU in September 2013, leading to expectations that the FDA would follow suit in the US.

Without the US market, Lemtrada is very unlikely to meet sales targets, and consequently Sanofi’s share price fell by 1.1%. Furthermore, one US law firm is launching a class action on behalf of investors, claiming the French company made misleading statements about the prospects for alemtuzumab.

In a press release, a spokesperson for Genzyme stated that they strongly disagree with the conclusions and plan to appeal against the FDA’s decision.


Related Content

High hopes

3 February 2015 Feature

news image

Cannabinoids are finally coming out of the shadows and onto the shelves of pharmacies around the globe. Rachel Brazil reports

2012 pharma industry roundup

3 January 2013 Business

news image

What were the bigger stories? And how did the industry fare overall?

Most Read

Sun rises on new solar route to hydrogen

27 February 2015 Research

news image

Photocatalyst has solar-to-hydrogen conversion efficiency of 2% and points way to cheap production of the gas

The mothers of invention

24 February 2015 Managing Change

news image

Nina Notman profiles four researchers successfully balancing an academic career with family life

Most Commented

Sun rises on new solar route to hydrogen

27 February 2015 Research

news image

Photocatalyst has solar-to-hydrogen conversion efficiency of 2% and points way to cheap production of the gas

Hepatitis C drug patent challenged in Europe

19 February 2015 Business

news image

Campaign group says Gilead’s expensive blockbuster sofosbuvir is not innovative enough to warrant a patent